Nasus Pharma Ltd.
NSRXAMEXHealthcareMedical - Pharmaceuticals
Latest quote
$4.00
+$0.15 · +3.90%
NSRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
48
Fair Value
Momentum
24
Weakening
Sentiment
43
Mixed
Risk resilience
4
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteNasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Brendan O'Grady
- Listed since
- Aug 13, 2025
- Employees
- 7
Market position
- Volume
- 29.89K
- 0.83× average
- Average volume
- 35.81K
- Average daily volume
- Market cap
- 34.45M USD
- Beta
- 3.96
- Market reference 1
Continue in GoAI
Research NSRXresearch.disclaimer